human sICAM-1 ELISA kit (48 Wells)

Intercellular Adhesion Molecule 1 (ICAM-1), also known as CD54, is a nearly ubiquitous transmembrane glycoprotein that plays a key role in leukocyte migration and activation (1, 2). Human ICAM-1 contains five Ig-like domains in its extracellular domain (ECD) and associates into non-covalently linked dimers (3, 4). Soluble forms of monomeric and dimeric ICAM-1 (sICAM-1) can be generated via proteolytic cleavage by cathepsin G, elastase, MMP-9, MMP-14/MT1-MMP, and TACE/ADAM17 (5 - 8). In the mouse, alternate splicing generates isoforms that lack particular Ig-like domains and are differentially sensitive to proteolysis (5). Within the ECD, human ICAM-1 shares 53% amino acid sequence identity with mouse and rat ICAM-1. The principal binding partners of ICAM-1 are the leukocyte integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) (9 - 11). The multivalency of dimeric ICAM-1 increases its strength of interaction with LFA-1 (9, 10). ICAM-1 also binds several non-integrin ligands including CD43/sialophorin, fibrinogen, hyaluronan, rhinoviruses, and Plasmodium falciparum-infected erythrocytes (12 - 16). At sites of inflammation, ICAM-1 is upregulated on endothelial and epithelial cells where it mediates the adhesion and paracellular migration of leukocytes expressing activated LFA-1 and Mac-1 (17 - 20). ICAM-1 ligation prolongs antigen presentation by dendritic cells and promotes T cell proliferation and cytokine release (21 - 23). ICAM-1 activation also participates in angiogenesis, wound healing, and bone metabolism (24 - 26). Soluble ICAM-1 has been reported in serum, cerebrospinal fluid, urine, and bronchoalveolar lavage fluid (2, 27 - 31). Elevated levels of sICAM-1 in these fluids are associated with cardiovascular disease, type 2 diabetes, organ transplant dysfunction, oxidant stress, abdominal fat mass, hypertension, liver disease, and certain malignancies (32 - 40). sICAM-1 promotes angiogenesis and serves as an indicator of vascular endothelial cell activation or damage (41, 42). It also functions as an inhibitor of transmembrane ICAM-1 mediated activities such as monocyte adhesion to activated endothelial cells and sensitivity of tumor cells to NK cell-mediated lysis (7, 8). For the quantitative determination of human soluble Intercellular Adhesion Molecule 1 (sICAM-1) concentrations in cell culture supernates, serum, and plasma. Principle of the assay: This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for sICAM-1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any sICAM-1 present is bound by the immobilized antibody. Following incubation unbound samples are removed during a wash step, and then a detection antibody specific for sICAM-1 is added to the wells and binds to the combination of capture antibody- sICAM-1 in sample. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Following incubation and wash steps a substrate is added. A coloured product is formed in proportion to the amount of sICAM-1 present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450nm. A standard curve is prepared from seven sICAM-1 standard dilutions and sICAM-1 sample concentration determined.

Intercellular adhesion molecule 1, Major group rhinovirus receptor, CD54

31 pg/ml